PACB Pacific Biosciences of California
Company Analysis
Latest News
🟢 Pacific Biosciences is trading 5% up today
Pacific Biosciences is trading higher at $1.21, up 5.21%, though no clear company-specific catalyst has been identified. • PacBio’s latest listed releases...
🟢 Pacific Biosciences is trading 5% up today as softer producer prices lift broader markets
Pacific Biosciences is trading 5.05% up at $1.17, moving alongside stronger broader markets on August 13, 2026, as softer-than-expected producer prices...
🔴 Pacific Biosciences is trading 6.14% down today
Pacific Biosciences is trading 6.14% down now at $1.07, with no fresh company-specific announcement identified for August 12, 2026. - The Nasdaq Composite is...
🔴 Pacific Biosciences is trading 5.29% down today after August 5 revenue miss and guidance cut
Pacific Biosciences is trading at $1.12 (-5.29%), with recent selling pressure following its August 5 earnings report. - The report showed a revenue miss,...
PacBio Drops 10% as Investors Flee Before Earnings — But Can a New CEO and Deeper Cost Cuts Save a Sub-$500M Company?
Shares of Pacific Biosciences tumbled 10.8% to $1.28 as investors rushed to sell ahead of the DNA-sequencing company's Q2 2026 earnings report, scheduled for...
🔴 Pacific Biosciences is trading 10.77% down today after lowered 2026 revenue guidance
Pacific Biosciences is trading 10.77% down now at $1.16 after its August 5, 2026 earnings release showed $39.0 million in second-quarter revenue, below...
Pacific Biosciences' second quarter revenue of $39M misses estimates as the company lowers its full-year outlook.
Pacific Biosciences of California reported second quarter revenue of $39.0 million, a 2% decrease year-over-year, missing analyst estimates of $41.0 million....
🔴 Pacific Biosciences is trading 10.8% down today ahead of Q2 earnings release
Pacific Biosciences is trading 10.8% down at $1.28 as investors de-risk ahead of its Q2 2026 earnings report scheduled for release this afternoon. • Market...
🔴 Pacific Biosciences is trading 5.6% down today ahead of Q2 earnings
Pacific Biosciences is trading 5.6% down today at $1.36 as investors position ahead of its Q2 2026 earnings report scheduled for release this afternoon. • The...
Pacific Biosciences of California Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Pacific Biosciences of California to report Q2 2026 revenue of $41.0 million and a net loss of $0.14 per share, with the stock currently...
🔴 Pacific Biosciences is trading 5.1% down today amid a broader biotech sector pullback
Pacific Biosciences is trading 5.1% down at $1.41 as the broader biotech sector retreats and market risk appetite cools. • The move tracks a roughly 3% drop...
🟢 Pacific Biosciences is trading 5.4% up today amid biotech sector strength and market rally
Pacific Biosciences is trading 5.4% up at $1.48, moving in line with a strong risk-on session in U.S. equities and a broader rally across the biotechnology...
🔴 Pacific Biosciences is trading 5% down today on light, news-less trading
Pacific Biosciences is trading 5% down at $1.33 on light, news-less trading. • The move appears to be driven by idiosyncratic volatility following recent...
🔴 Pacific Biosciences is trading 5.5% down today as multi-day slide continues after weak Q1 results
Pacific Biosciences is trading 5.5% down at $1.36 as the stock extends a multi-day slide following a weak first-quarter earnings report and revenue...
🔴 Pacific Biosciences is trading 5.3% down today following the resignation of board member Christopher M. Smith
Pacific Biosciences is trading 5.3% down today at $1.52 after investors reacted to the sudden resignation of board member Christopher M. Smith, announced on...
PACB Announces Resignation of Board Member Christopher M. Smith
Pacific Biosciences of California, Inc. (PACB) announced that Christopher M. Smith, a member of its board of directors, has resigned from the Board, effective...
🟢 Pacific Biosciences is trading 10.3% up
Pacific Biosciences is trading at $1.66, up 10.3% from a comparison close of $1.50 during regular trading. This is a price-action follow-up, so a separate...
PacBio Bounces 9% Off Its Lows, but Can a Gene-Sequencing Company Burning Cash Outrun a Shrinking Revenue Ceiling?
Shares of Pacific Biosciences shifted sharply higher on July 9, rising 9% to $1.64 after touching $1.50 the prior session — a slide that capped a week-long...
🟢 Pacific Biosciences is trading 7.67% up today as it rebounds from a selloff following a revenue guidance cut
Pacific Biosciences is trading at $1.64 (+7.67%) as the stock stages a sharp rebound from the previous session's selloff. • The recent downward pressure...
🔴 PACB is trading 5.1% down today on lowered 2026 guidance and small-cap biotech volatility
PACB is trading 5.1% down at $1.48 amid continued volatility in small-cap biotech and lingering reaction to its mixed Q1 2026 results. • Recent coverage...